Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Southwest Airlines Co (LUV) Price & Performance

Ascendis Pharma A/STrade
Southwest Airlines CoTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Southwest Airlines Co — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Southwest Airlines Co trades at $45.71 (market cap $21.97B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDLUV
Market Cap
$16.78B$21.97B
Sector
HealthIndustrials
52-Week High
$277.18$54.80
52-Week Low
$189.74$29.67
Enterprise Value
$17.15B$25.06B
Dividend Yield
1.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.

ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.

Southwest Airlines Co

Southwest Airlines (LUV) trades at $47.05, up 0.23% today, with a bullish technical signal and consensus price target of $53.86. Recent Q2 2026 earnings beat expectations with EPS of $0.94 versus $0.51 expected, driven by record revenue. The company maintains a solid liquidity position of $8.73B cash and has declared quarterly dividends of $0.18 per share, with new board appointments signaling strategic focus.

Outlook is positive with projected 2026 net income margin of 2.78% and revenue growth to $30.1B, but risks include fuel cost volatility and competitive pressures. Analyst sentiment is mixed with 42% buy ratings, offering potential upside of 14.5% to the consensus target, though institutional selling by firms like Elliott Management warrants monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Southwest Airlines Co

Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.

Read more on LUV